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following hepatitis B (HBV) infection. However, the high rate of recurrence of HBV infec-
tion following transplantation is a disadvantage of this option.
Evidence Acquisition: Over the past 2 decades, the gold standard of prophylactic treat-
ment for the prevention of HBV re-infection following liver transplantation has been the 
administration of low- to high-dose hepatitis B immune globulin (HBIg) along with an 
antiviral agent to induce passive immunity. 
Results: The eﬀectiveness of HBIg in preventing the recurrence of HBV depends on the 
dosage, route of administration, and duration of HBIg treatment, and the viremic status 
at the time of transplantation. There is currently no consensus on a standardized recom-
mendation for therapeutic options that include HBIg administration.
Conclusion: This review attempts to summarize the available data on the feasibility of 
such options. Most recent studies support the use of long-term combination therapy of 
HBIg and antiviral NAs (especially new agents). 
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1. Context
Globally, 30% of cirrhosis cases and 53% of primary liver 
cancer cases are attributed to hepatitis B infection (1), for 
which liver transplantation (LT) has been the only stan-
dard treatment option (2). However, the success of LT has 
been complicated by the high incidence (80%–100%) of 
recurrent graft infections, which typically occur between 
6 and 12 months after LT in the absence of prophylaxis 
(3). This is accompanied by subsequent graft failure, rap-
id progression to cirrhosis, fulminant hepatitis, and pa-
tient death. The frequency of HBV reinfection is the low-
est in HBV-immune recipients (0%–18%) and is the highest 
in HBV-naive recipients (70%–80%) (2, 4-9). Reinfection 
has been hypothesized to occur due to the presence of 
circulating virions at the time of LT, exposure to extra-
hepatic reservoirs of HBV, or the persistence of the HBV 
covalently closed circular DNA (cccDNA) as a replicative 
intermediate (8, 10, 11). Furthermore, candidates under 
immunosuppressive therapy following LT commonly 
show a decrease in antibody titers (12) and an increase in 
viral replication (11, 13). Such active viral replication at the 
time of LT (> 105 copies/mL) was shown to be an impor-
tant factor aﬀecting HBV recurrence, sometimes regard-
less of immunoprophylaxis therapy (6, 14, 15). Moreover, 
hepatitis B infection in LT recipients who have received 
grafts from hepatitis B core antibody positive donors is a 
serious medical concern (16). Therefore, HBV-related liver 
disease was initially regarded as a contraindication to LT 
(17, 18). The morbidity and mortality caused by recurrent 169 Hepat Mon. 2012
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HBV infection after LT were signiﬁcant before the advent 
of eﬀective immunoprophylaxis (19). However, in the 
last 2 decades, the indication for LT in patients with HBV-
related end-stage liver disease has changed dramatically, 
and prophylactic strategies against HBV reinfection have 
changed outcomes for patients who undergo LT (20, 21). 
With adequate prophylaxis, less than 10% of the patients 
with HBV recurrence have to undergo repeated LT due to 
HBV-related graft failure (10, 22, 23).
2. Evidence Acquisition
The primary purpose of this review was three-fold. 
Our ﬁrst aim was to clarify the eﬀectiveness of diﬀerent 
routes of administration, durations, and dosages of HBIg 
prophylactic options. The second aim was to compare 2 
therapeutic options: HBIg monotherapy and HBIg ther-
apy in conjunction with nucleos(t)ide analogues (NAs). 
Our third and ﬁnal aim was to summarize the available 
studies on the diﬀerent prophylaxis protocols used to 
prevent HBV recurrence in transplant recipients. A com-
prehensive search was performed in PubMed with the fol-
lowing Mesh search keywords: liver transplantation and 
HBIg monotherapy, liver transplantation and HBIg com-
bination with NA, HBIg, and hepatitis B surface antigen 
(HBsAg) variants in liver transplantation. All published 
data from 1989 (the discovery of surface mutants) to Au-
gust 2011 have been included in this review. Studies on 
the impact of HBIg monotherapy or HBIg therapy along 
with NAs on the HBV recurrence rate post-LT, HBIg route, 
dosage, and treatment, or mutations caused by the selec-
tive pressure following HBIg therapy were included in 
our analyses. Data were analyzed on the basis of sample 
size, rate of recurrence, and presence or absence of NAs 
in the diﬀerent prophylactic protocols.
3.Results
3.1. HBIg and the Prophylactic Options
Over the past 2 decades, the gold standard of prophylac-
tic treatment for the prevention of HBV reinfection fol-
lowing LT has been the inducement of passive immunity 
by administering low- to high-dose HBIg with or without 
antiviral NAs (10). However, a consensus on the dose, 
duration, or route of administration of HBIg for the pre-
vention and/or suppression of HBV reinfection post-LT is 
lacking, and protocols tend to vary widely from 1 trans-
plant center to another (24-27). However, with respect to 
the best practice for prophylactic strategies, most trans-
plant programs in diﬀerent centers around the world 
use the following 3 steps in general:
1) Intravenous administration of HBIg (4000–10,000 
IU/mL) during the anhepatic phase. 
2) Daily intramuscular or intravenous administration 
of 2000 to 10,000 IU HBIg for the ﬁrst 3–7 days following 
LT. 
3) High-dose therapy with 10,000 IU of HBIG every 4 
weeks post-transplantation or low-dose therapy (400–
2000 IU of HBIG) every 2 weeks post-transplantation to 
maintain anti-HBs > 100 IU/L (10, 27). 
3.2. Route of HBIg Administration
3.2.1. Intravenous Route
Traditionally, HBIg has been administered, pre-and 
postoperatively, at high doses, through the intravenous 
(IV) route. (Table 1) (4, 5, 15, 19, 25, 28-37). Despite the re-
ported success of this method in preventing HBV re-
currence post transplantation, high costs and patient 
incompliance have limited the acceptance of this ap-
proach.
3.2.2. Intramuscular Route
The administration of low dose intramuscular (IM) 
HBIg has been discussed as an accepted alternative route 
to IV administration in several studies worldwide (Table 
1) (2, 3, 14, 38-52). However, given the limited volumes 
that can be given per IM injection, only patients with 
low HBIg requirements are suited for IM HBIg adminis-
tration (9, 53). A crossover study employed alternative 
IM and IV regimens; in that study, intraindividual varia-
tion in antibody levels following IM and those following 
IV administration of HBIg were observed, but the overall 
anti-HB antibodies concentrations and half-lives in dif-
ferent individuals were not signiﬁcantly diﬀerent (54).
3.2.3. Subcutaneous Route
Two studies on the subcutaneous (SC) administration 
of HBIg, either alone or in combination with lamivudine 
(LAM), to prevent recurrent HBV infection in patients 
who had chronic hepatitis B before LT showed that SC 
administration of HBIg can eﬀectively maintain satis-
factory levels of anti-HB antibodies (Table 1). Both stud-
ies suggested SC delivery of HBIg as an alternative when 
IM or IV dosing are not possible (55, 56). The beneﬁts of 
SC administration of HBIg include the potential for self-
administration by patients, lower dosage (500–1000 IU), 
few adverse drug eﬀects, stability of anti-HB levels, and 
an especially low recurrence rate (21, 54-56).
3.3. HBIg Dose
3.3.1. High Dose HBIg Regimen
Numerous reports from diﬀerent centers have shown 
that the continuous use of high-dose HBIg post-LT dra-
matically reduces the incidence of recurrent HBV infec-
tions. The high dose regimen was pioneered by Samuel 
et al., who showed that HBV infection could be reduced 
in frequency by administration of high doses of HBIg for 
more than 6 months after LT (20). Later, 2 studies from 
the United States used aggressively high doses of IV 
HBIg, and subsequently, the recurrence rate reduced by 
more than 20% (57, 58). Thus, long-term, high-dose HBIg 
became the standard prophylaxis for HBV reinfection in 
most transplant centers in the 1990s, prior to the avail-
ability of eﬀective antiviral therapies (11). Further studies 
indicated that HBV reinfection could be prevented in ma-170 Hepat Mon. 2012
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jority of patients by using high-dose HBIg protocols and 
subsequent close monitoring of anti-HB antibody titers 
to prevent prophylaxis failures, especially in patients 
with high HBV DNA pre-LT (Table 1) (4, 5, 15, 19, 25, 28-37, 
52). Despite monitoring, patients with active replication 
still had a 16% rate of HBV recurrence. Subsequently, out-
comes of a combination of high-dose IV HBIg and LAM 
were extensively investigated, and several studies report-
ed a lower HBV recurrence rate (< 10% at 1- to 2-year follow-
up) with this combination treatment (Table 1) (19, 21, 40, 
59, 60). However, the application of long-term high dose 
HBIg has been associated with high costs, inconvenience 
to patients, and the emergence of surface Ag mutations 
(4, 6, 10, 53, 61, 62).
3.3.2. Low Dose HBIg Regimen
Some reports have shown that the eﬃcacy of the low-
dose HBIg and LAM combination therapy is similar to 
that of the high-dose protocol (Table 1) (41, 42, 47). In sev-
eral studies, administration of HBIg at low doses (300–
800 IU) through the IM rather than the IV route has been 
shown to reduce the cost of prophylactic therapy, mak-
ing the low-dose protocol as eﬀective as the high-dose 
protocol (7, 8, 14, 19, 38, 39, 41-51, 59, 63) (Table 1). As a re-
sult of the combination with lamivudine, this approach 
was associated with similar recurrence rate and survival 
(40, 42) that could eﬀectively prevent HBV recurrence af-
ter liver transplantation (2). Further, pre-LT reduction in 
viral replication makes the above combination therapy 
more eﬀective (20, 40). Clearly, lower doses of HBIg (300–
800 IU) and administration through the IM rather than 
the IV route reduce the cost of prophylactic therapy (8, 
14, 19, 40, 42, 59). Currently, in several transplant centers 
in the United States, use of low doses of HBIg and a more 
limited duration of therapy have been shown to be suf-
ﬁcient in preventing HBV recurrence, as long as the ap-
propriate therapy is started (64).
3.4. Indeﬁnite Versus Short-Term Approaches
Indeﬁnite HBIg prophylaxis may be required for pa-
tients with active replication at the time of initiation of 
LAM treatment (29). Lifelong prophylaxis by the adminis-
tration of HBIg in combination with NAs has resulted in 
a signiﬁcant reduction in recurrent hepatitis B (Table 1) 
(10, 17, 37, 65). Currently, this approach is being employed 
in many transplant centers in the United States, despite a 
lack of signiﬁcant diﬀerences between the diﬀerent HBIg 
regimens in terms of HBV recurrence 5 years after LT (65). 
Although compared to other treatments, indeﬁnite, high 
dose HBIg treatment combined with NAs is thought to be 
very eﬀective, the cost of this treatment is very high and 
as a result, in recent years, several centers have preferred 
to use short-term HBIg treatment in combination with 
indeﬁnite nucleos(t)ide analogue therapy (Table 1) (6, 8, 
38). Moreover, indeﬁnite combination therapy with HBIg 
and a NA may not be required in all liver transplant re-
cipients. Both discontinuation of HBIg and/or NAs after 
a deﬁned interval or continued treatment with antivirals 
alone (9, 35, 43, 63) have been applied by some centers 
with promising results; these centers have achieved rate 
of recurrence between 0% and 12.9% (Table 1).
3.5. Hepatitis B Immunoglobulin Monotherapy
Some studies showed that HBIg monotherapy ap-
peared to be equivalent to combination therapy (HBIg 
plus antiviral NA) for prevention of HBV post-LT as be-
ing more eﬀective at reducing the re-infection rate (21, 
66). Protocols for monotherapy with high doses of HBIg 
(10,000 IU) have been used during the anhepatic phase 
followed by daily dosing during the ﬁrst few days post-
transplantation, with subsequent continuation adapted 
according to serum anti-HB antibody titers to be either 
short term (6 to 12 months) or indeﬁnite (Table 1) (4, 5, 
14, 15, 19, 28, 30-32, 34-38, 41, 47, 48, 52, 57, 67). Long-term 
HBIg monotherapy is generally well tolerated, although 
mild to moderate adverse events have been noted (21, 53). 
However, due to the risk of late reinfection, especially in 
patients with active pre-LT replication of HBV (and par-
ticularly those with a viral load greater than 105 copies/
mL), HBIg monoprophylaxis might not be a successful 
solution (Table 1) (4, 11, 15, 20, 68). Furthermore, mono-
therapy with HBIg has been shown to promote muta-
tions in the surface genes, which may lead to a reduction 
in the eﬃcacy of HBIg (4, 8, 10). Therefore, to overcome 
this problem, combination therapy of HBIg with NAs was 
introduced and has been accepted as being more eﬀec-
tive at reducing the reinfection rate.
3.6. Combination Treatment of NAs With HBIg
The risk of recurrent hepatitis and death in transplant 
recipients has been lowered with the development of 
new antiviral agents, and the combined use of HBIg and 
these agents is associated with lower recurrence rates 
than HBIG or NA monotherapy. This prophylactic strat-
egy includes potential concerted eﬀects between HBIG 
and NA as well as shorter courses or lower doses of HBIG. 
In general, protocols for HBIg and antiviral NA combina-
tion therapy consist of pre-transplantation administra-
tion of antiviral agents (especially in HBV-DNA-positive 
patients) to reduce the viral load, followed by high doses 
of IV HBIg (10,000 IU/day) during the anhepatic phase, 
and a combination of long term antiviral NA and IV or IM 
HBIg following transplantation (21, 69). The use of combi-
nation therapy has become a common strategy to reduce 
post-LT HBV recurrence rates, and its eﬃcacy has been in-
vestigated extensively (6, 39-41, 44, 46, 51, 63). Combina-
tion therapy appears to be an eﬀective strategy for reduc-
ing HBV recurrence to 0 and 16% (Table 1) (6, 39-41, 44, 46, 
51, 63), and for bringing about >90% long-term negativity 
for HBsAg (70, 71). Further, combination therapy is more 
cost eﬀective because the dosage of HBIg, which is expen-
sive, can be reduced, making NA and HBIg combination 
therapy far more economically attractive and potentially 
more widely available (17, 19, 40, 43, 44, 72-76). Some stud-171 Hepat Mon. 2012
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ies have used NA alone in cases of post-LT HBV recurrence 
(on patient’s demand) after administration of HBIg at 
doses currently deﬁned as high and low in the anhepatic 
phase and post-LT (Table 1) (25, 39, 67). However, combi-
nation protocols diﬀer amongst transplantation cen-
ters and, to some extent, the reported results have been 
limited by small sample sizes and short-term follow-up. 
Nonetheless, the main problem with the use of antiviral 
substances before and/or after LT seems to be the evolu-
tion of resistant viral mutations, especially in high-risk 
patients (6, 31, 45, 77, 78). New treatment options such as 
adefovir dipivoxil (ADF) and entecavir have been shown 
to prevent post-LT HBV infection (25), resulting in im-
proved survival in HBV-infected transplant recipients 
(24-26) 
3.7. New NAs 
Among the new NAs, adefovir (ADF) has been evaluated 
in diﬀerent studies as a treatment option in transplant 
settings (15, 25, 31, 32, 39, 41, 49-51, 63) (Table 1). ADF ther-
apy successfully suppressed HBV DNA replication and 
improved or stabilized HBV infection recurrence after LT 
(15, 39). LAM-resistant cases despite HBIg and lamivudine 
combination prophylaxis responded well to the addi-
tion of ADF to therapy or upon switching to ADF (4, 25, 32, 
39, 63). Some studies have used entecavir, both with and 
without HBIg, with promising outcomes and without 
any cases of HBV recurrence during the follow-up period 
(4, 65, 79-82). A few studies on new NA drugs (ADF and en-
tecavir) have also shown the eﬀectiveness of these agents 
in the suppression of HBV replication in patients who 
developed lamivudine-resistance variants post-LT (Table 
1). Although the use of these new antivirals for the pro-
phylaxis of recurrent HBV infection is increasing with-
out a concomitant increase in viral resistance, very few 
studies address the diﬀerences in the eﬀect of the use of 
these new NAs as monotherapies or in combination with 
HBIg. Therefore, further studies are needed to test the ef-
fectiveness of these antivirals in combination therapies 
with HBIg and as monotherapeutic strategies (79, 83, 84). 
4. Conclusions
Although a standard prophylactic regimen after LT is 
not available, the available systematic reviews and me-
ta-analyses of clinical studies from multiple literature 
sources support the use of long-term combination ther-
apy of HBIg and antiviral NAs (especially new agents).
Regarding the combination strategy, the individualized 
prophylaxis protocols still are feasible, eﬀective, but 
highly expensive. Most of the studies have a very small 
sample size that signiﬁcantly limits the power of their 
ﬁndings. Future prospective multicenter and cohort 
studies with a longer period of follow up are needed to 
better deﬁne post-LT prophylactic strategies.
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